Melya Crameri
Directeur/Membre du Conseil chez Ilya Pharma AB
Profil
Melya Hughes Crameri is currently the Director at Ilya Pharma AB.
She previously worked as the Head-Human Resources at Evolva SA starting in 2009.
Before that, she held positions as a Researcher at Merck & Co., Inc., and as a Legal Counsel at Geron Corp.
and Cooley Godward LLP.
Dr. Crameri obtained a doctorate degree from the University of Basel.
Postes actifs de Melya Crameri
| Sociétés | Poste | Début |
|---|---|---|
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Responsable des Ressources Humaines | 01/01/2005 |
Ilya Pharma AB
 Ilya Pharma AB BiotechnologyHealth Technology Ilya Pharma AB develops biological drugs for treating wounds in skin and mucosa. The company was incorporated in May 13, 2016 by Mia Johanna Phillipson, Stefan Roos and Evelina Wanda Matilda Vågesjö and is headquartered in Uppsala, Sweden. | Directeur/Membre du Conseil | - |
Anciens postes connus de Melya Crameri
| Sociétés | Poste | Fin |
|---|---|---|
Cooley Godward LLP
 Cooley Godward LLP Miscellaneous Commercial ServicesCommercial Services Cooley Goodword LLP is the law firm specializes in providing services to both new and established information technology and life sciences companies. Cooley also provides counsel in areas of business law that include trade regulation, employment and labor, investment banking issues, securities litigation, IPOs, mergers and acquisitions, patent enforcement and venture capital funding. It is located in Palo Alto, CA. | Conseiller Juridique Général | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| GERON CORPORATION | Conseiller Juridique Général | - |
Formation de Melya Crameri
| University of Basel | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Cooley Godward LLP
Cooley Godward LLP Miscellaneous Commercial ServicesCommercial Services Cooley Goodword LLP is the law firm specializes in providing services to both new and established information technology and life sciences companies. Cooley also provides counsel in areas of business law that include trade regulation, employment and labor, investment banking issues, securities litigation, IPOs, mergers and acquisitions, patent enforcement and venture capital funding. It is located in Palo Alto, CA. | Commercial Services |
Ilya Pharma AB
Ilya Pharma AB BiotechnologyHealth Technology Ilya Pharma AB develops biological drugs for treating wounds in skin and mucosa. The company was incorporated in May 13, 2016 by Mia Johanna Phillipson, Stefan Roos and Evelina Wanda Matilda Vågesjö and is headquartered in Uppsala, Sweden. | Health Technology |